CliffBio
biologic

Roctavian

valoctocogene roxaparvovec-rvox

Loss of exclusivityJune 2035projected — 12-year biologic exclusivity estimate
CompanyBiomarin Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameRoctavian
Active ingredientvaloctocogene roxaparvovec-rvox
Strength16X 10E13GENOMES PER ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2023
Marketing statusRx

More from Biomarin Pharmaceutical

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Roctavian patent cliff — loss of exclusivity June 2035 | CliffBio